Literature DB >> 2899610

Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction?

H D Thames1, K K Ang, F A Stewart, E van der Schueren.   

Abstract

Recent evidence indicates that isoeffect doses for spinal cord and kidney may be overestimated for fraction sizes as small as 1 or 2 Gy when calculated from a linear-quadratic (LQ) model fitted to data obtained for fraction sizes larger than 2 Gy. Reasons for this are unknown, but possible interpretations include exhaustion of repair capacity and incomplete repair in experiments designed to study the response to these small doses. The latter interpretation is motivated by the relatively short intervals between multiple daily doses given to the spinal cord (4 h) and kidney (5 h) when fraction sizes were small. The possibility that overestimation of isoeffect dose could be explained by incomplete repair during short intervals between doses was assessed by fitting experimental data to the incomplete-repair model. For the spinal cord the data could be interpreted by assuming that a repair process with a half-time of 1.7 h was incomplete; this half-time is negligibly different from the estimate obtained from repair-kinetics experiments with larger doses per fraction. The deviation from the (complete-repair) LQ model could be interpreted for the kidney in terms of a half-time of repair of 2.8 h (a negligibly different fit was obtained with the value 1.5 h). The clinical implication could be that multiple-fractions-per-day treatment would benefit from use of the longest feasible interfraction interval when late reactions are dose limiting.

Mesh:

Year:  1988        PMID: 2899610     DOI: 10.1080/09553008814551461

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  7 in total

1.  [(111)In]DOTATOC as a dosimetric substitute for kidney dosimetry during [(90)Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.

Authors:  Alexander Stahl; Sylvia Schachoff; Ambros Beer; Anna Winter; Hans Jürgen Wester; Klemens Scheidhauer; Markus Schwaiger; Ingo Wolf
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-28       Impact factor: 9.236

2.  External beam radiotherapy for primary spinal cord tumors.

Authors:  H C Chun; R K Schmidt-Ullrich; A Wolfson; O F Tercilla; R H Sagerman; G A King
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

3.  The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model.

Authors:  Joseph J Grudzinski; Wolfgang Tomé; Jamey P Weichert; Robert Jeraj
Journal:  Phys Med Biol       Date:  2010-09-08       Impact factor: 3.609

4.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

Authors:  Lisa Bodei; Marta Cremonesi; Mahila Ferrari; Monica Pacifici; Chiara M Grana; Mirco Bartolomei; Silvia M Baio; Maddalena Sansovini; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-22       Impact factor: 9.236

5.  A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin).

Authors:  Massimiliano Pacilio; Margherita Betti; Francesco Cicone; Carolina Del Mastro; Livia Montani; Laura Chiacchiararelli; Alessia Monaco; Enrico Santini; Francesco Scopinaro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

6.  Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.

Authors:  Hendrik Bergsma; Mark W Konijnenberg; Wouter A van der Zwan; Boen L R Kam; Jaap J M Teunissen; Peter P Kooij; Katya A L Mauff; Eric P Krenning; Dik J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-10       Impact factor: 9.236

7.  Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy.

Authors:  Anna Sundlöv; Johan Gustafsson; Gustav Brolin; Nadja Mortensen; Rebecca Hermann; Peter Bernhardt; Johanna Svensson; Michael Ljungberg; Jan Tennvall; Katarina Sjögreen Gleisner
Journal:  EJNMMI Phys       Date:  2018-07-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.